Efficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinoma

Simple item page
dc.contributor.authorChunwang, Yuanen_US
dc.contributor.authorZhuhui, Yuanen_US
dc.contributor.authorXiongwei, Cuien_US
dc.contributor.authorWenfeng, Gaoen_US
dc.contributor.authorPeng, Zhaoen_US
dc.contributor.authorNing, Heen_US
dc.contributor.authorShichang, Cuien_US
dc.contributor.authorYang, Wangen_US
dc.contributor.authorYonghong, Zhangen_US
dc.contributor.authorWei, Lien_US
dc.contributor.authorJiasheng, Zhengen_US
dc.date.accessioned2020-11-18T10:07:22Z
dc.date.available2020-11-18T10:07:22Z
dc.date.issued2019-08
dc.description.abstractPurposes: This study aimed to investigate the efficacy of ultrasound (US)-, computed tomography (CT)-, and magnetic resonance imaging (MRI)-guided radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC). Materials and Methods: This retrospective study included 141 patients with HCC who were treated with US-guided (n = 29), CT-guided (n = 50), or MRI-guided RFA (n = 62). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), technique success (TS), and technique efficacy (TE). Cox model and logistic regression were used to determine the risk factors for tumor recurrence and TE. Results: The US, CT, and MRI groups did not show a significant difference in terms of baseline variables. The three groups did not differ significantly in PFS rate (P = 0.072) and OS rate (P = 0.231). The PFS rates at 3 years for the US, CT, and MRI groups were 40.90%, not reached, and 14.80%, respectively. The OS rates at 3 years were 94.70%, 97.50%, and 85.50% for US, CT, and MRI groups, respectively. No significant differences were observed between the three groups in terms of TS rate (P = 0.113) and TE rate (P = 0.682). In multivariate analysis, liver cirrhosis (P = 0.001), level of alpha-fetoprotein (AFP, P = 0.004), and number of tumors (P = 0.012) were independent risk factors for PFS. For TE, the level of AFP (P = 0.018) was an independent factor. Conclusion: US-, CT-, and MRI-guided RFA was effective for treating HCC patients. Liver cirrhosis, AFP level, and tumor number were associated with tumor recurrence, and the level of AFP was an independent risk factor affecting TEen_US
dc.identifier.affiliationsCenter of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, PR. Chinaen_US
dc.identifier.citationChunwang Yuan, Zhuhui Yuan, Xiongwei Cui, Wenfeng Gao, Peng Zhao, Ning He, Shichang Cui, Yang Wang, Yonghong Zhang, Wei Li, Jiasheng Zheng. Efficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinoma. Journal of Cancer Research and Therapeutics. 2019 Aug; 15(4): 784-792en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213431
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume15en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_836_18en_US
dc.titleEfficacy of ultrasound-, computed tomography-, and magnetic resonance imaging-guided radiofrequency ablation for hepatocellular carcinomaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2019v15n4p784.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics